

# CANCER JOURNAL

WINTER 2019

SURVIVORSHIP

## Battling Breast Cancer with a Newborn

Selvy Azer's path to pregnancy was not an easy one. Azer, 33, and her husband of 12 years had been trying to have a baby for a while, and finally got pregnant after their third cycle of in vitro fertilization.

As Azer approached the end of her pregnancy, her excitement was dampened when her doctor, Hany Ahmed, MD, an OB-GYN affiliated with Memorial Hermann Greater Heights Hospital, discovered a mass in her breast.

"My family has a long history of breast cancer," Azer says. "I started getting annual mammograms when I was 30 years old, and I was good about doing self-checks."

Dr. Ahmed referred her to Mike Ratliff, MD, surgeon and breast cancer specialist affiliated with Memorial Hermann Cancer Center-Greater Heights. After she was diagnosed with breast cancer, Dr. Ratliff approved her for early delivery so that she could begin her cancer treatment right away.

"In our multidisciplinary Breast Cancer Conferences, we discuss each patient's case in detail and reach a consensus on an individualized treatment plan," Dr. Ratliff says. "All decisions are based on research and data from the National Comprehensive Cancer Network, which makes for outstanding cancer care. We're very proud of the care we provide at Memorial Hermann Greater Heights."

Azer had a mixed reaction to her diagnosis of breast cancer. "I don't like to complain about things and burden people," she says. "The more I complain, the weaker I feel. There

were tears, and there was laughter. Laughter helps me cope with things."

She delivered a healthy baby girl, Gianna, at Memorial Hermann Greater Heights in January 2019. "Gianna is a happy baby," Azer says. "I was so thankful that all of this came at the end of the pregnancy and that it didn't impact my little bundle of joy. All of my doctors were so supportive and even came to visit me in the hospital after I had my baby."

She began chemotherapy two weeks after delivering Gianna. She had more than a dozen treatments between February and July of 2019, all while raising a newborn.

"I didn't have the luxury of staying in bed, tired," Azer says. "Gianna gave me a lot of energy during all that time. I think she actually helped me get through the treatment. I never had time to sit and feel sick."

Azer underwent a bilateral mastectomy after completing chemotherapy, followed by breast reconstruction. Her physician team recommended a double mastectomy to reduce the risk of a recurrence.

"Mrs. Selvy tested positive for BRCA, which indicates a high likelihood of occurrence of breast cancer in either breast," Dr. Ratliff says. "Bilateral mastectomy is standard for patients who are BRCA positive, but it's always the patient's decision on how to proceed. Her willingness to have the surgery shows how terrific and courageous she is, and how much she wants to live a healthy life for her husband and her daughter."

Azer is now cancer free. "I think my



"I didn't have the luxury of staying in bed, tired," Azer says. "Gianna gave me a lot of energy during all that time. I think she actually helped me get through the treatment. I never had time to sit and feel sick."

- Selvy Azer

attitude made things go as smoothly as they could," she says. "I am always energetic and I think that kept me from being too fatigued. I had fun switching up wigs and hair colors from time to time. I did my best to not look sick."

MEMORIAL  
HERMANN  
Cancer Centers

# Prostate Cancer Free for 13 Years: The Importance of Annual Screenings



In the early 2000s, José Melgar was encouraged by his employer to get a yearly blood test to screen for prostate cancer. The test measures the amount of prostate-specific antigen (PSA) in the blood, a protein produced by cancerous and noncancerous tissue in the prostate. Elevated levels of PSA may indicate prostate cancer.

“My test results were fine, but my PSA numbers were going up little by little, year after year,” Melgar says. “I had an annual physical with my primary care physician. He saw the increasing numbers from my PSA test and recommended that I see a urologist.”

In early 2006, Melgar’s urologist performed a biopsy of his prostate. Samples revealed that Melgar had asymptomatic early stage prostate cancer. He referred him to Andrew Selzman, MD, chair of urology at Memorial Hermann Memorial City Medical Center. Because of Melgar’s age - 48 at the time - Dr. Selzman recommended robotic-assisted prostatectomy. The minimally invasive surgery typically offers a faster recovery time with less pain and lower risk of complications.

“My surgery was the Monday after the 2006 Super Bowl,” Melgar says. “I had the procedure on Monday and left the hospital on my own on Tuesday.” Thirteen years later, Melgar is still cancer free.

“After my surgery I met a lot of men who don’t go to the doctor for an annual exam. I talk to them about my history, and I always recommend getting an exam just to be safe.”

- José Melgar

“I see Dr. Selzman every year,” he says. “After my surgery I met a lot of men who don’t go to the doctor for an annual exam. I talk to them about my history, and I always recommend getting an exam just to be safe.”

Many men with early stage prostate cancer do not exhibit symptoms, which is why an annual exam is important. Those who experience pain during urination, inability to urinate, blood in semen or urine, or pain in the upper thighs, hips or lower back should consult a physician.

The American Cancer Society and American Urological Association advise men 50 years and older to have an annual PSA test and digital rectal exam. African-American men and those with a family history of prostate cancer should have tests done each year beginning at age 40.

Researchers don’t know what causes prostate cancer, but some studies suggest that eating fruits and vegetables and limiting fat intake may offer some protection.

To learn more about prostate cancer and screening, visit <https://cancer.memorialhermann.org/prostate-cancer>.

## IN THIS ISSUE

### **SURVIVORSHIP 1-3**

**Battling Breast Cancer with a Newborn**

**Prostate Cancer Free for 13 Years:  
The Importance of Annual Screenings**

**The Cancer That Wasn't**

### **EXCELLENCE IN CANCER CARE 3-4**

**McGovern Medical School Establishes  
Hematology and Medical Oncology  
Fellowship Program**

**In Memoriam: Robert J. Amato, DO**

### **A NOTE FROM LEADERSHIP 5**

### **PROFILE IN CARING 6**

**Tam Huynh, MSN, RN, FNP-C, CBCN,  
AOCNP**

### **ADVANCES IN CANCER TREATMENT 6-7**

**LINAC Edge Provides Greater Radiation  
Precision at the Memorial Hermann  
Cancer Center-TMC**

**Robotic Whipple Procedure Offers  
Hope for Pancreatic Cancer Patients  
Diagnosed Early**

### **RESEARCH 7-9**

**OnOngoing Clinical Trials**

### **VOLUNTEER SPOTLIGHT 10-11**

**A Handshake Between Memorial  
Hermann and American Cancer Society**

**Memorial Hermann Rolls Out New Lay  
Patient Navigator Program with the Help  
of CanCan**

### **COMMUNITY OUTREACH 11-14**

**Project Mammogram Provides Breast  
Care Services for Underserved Women  
in Northeast Houston**

**In the Pink of Health Raises Nearly  
\$750,000 to Help Fight Breast and  
Ovarian Cancer**

**Memorial Hermann Celebrates 10th  
Anniversary of Razzle Dazzle Luncheon**

**Memorial Hermann Memorial City Holds  
Prostate Cancer Seminar and Breakfast**

### **MEMORIAL HERMANN WELCOMES 14**

### **IN PRINT 15**

# The Cancer That Wasn't

Maxine Davis's colonoscopy came out fine. Because of her family history of cancer of the duodenum, her gastroenterologist affiliated with Memorial Hermann Southeast Hospital, Sri Naveen Surapaneni, MD, recommended an esophagogastroduodenoscopy (EGD) to examine the lining of the esophagus, stomach and upper duodenum. He discovered a large polyp in the small intestine, and although no cancer cells were found on biopsy, the size of the polyp - and her family history - put her at high risk for cancer. Dr. Surapaneni gave her the names of three surgeons to consider.

"I liked Dr. Wray the minute I met him," says Davis, 61, who owns Ray's BBQ Shack in southeast Houston. "He explained that he would do the surgery robotically, which would make recovery quicker. I wanted to get back to work as soon as possible."

Curtis Wray, MD, is a general and oncological surgeon affiliated with Memorial Hermann. He is an associate professor of surgery at McGovern Medical School at UTHealth and Cancer Liaison Physician (CLP) for the Harris

Health System Cancer Committee. His areas of clinical expertise include traditional open as well as minimally invasive surgery for gastric, liver, pancreas and colorectal cancers. He is also one of the few surgeons in Houston who performs the Whipple procedure robotically for removal of the head of the pancreas, the duodenum, the gallbladder and the bile duct, followed by a complex reconstruction.

"Based on Mrs. Davis's diagnosis, we felt she would be a good candidate for the Whipple procedure, also known as pancreaticoduodenectomy," Dr. Wray says. "The pancreas and duodenum are intimately associated, so removal of the large polyp involved the same approach."

The robotic Whipple procedure is a two-surgeon operation. For Davis's procedure, Dr. Wray worked in tandem with Shinil Shah, DO, FACS, an associate professor in the department of Surgery at McGovern Medical School and a general surgeon whose areas of specialty care include surgery of the



esophagus and stomach. The procedure was done at Memorial Hermann-Texas Medical Center, which has a robust robotic surgery program and serves as a training site for physicians from around the country.

"Mrs. Davis did well during the surgery and postoperatively," Dr. Wray says. "Her level of activity after surgery was excellent."

Davis says she was out of the hospital within a week. "I had a very good experience," she says. "The nurses made sure I was comfortable throughout my stay, and Dr. Wray checked on me at least twice a day. They answered all our questions and kept my family updated about my progress from beginning to end."

## EXCELLENCE IN CANCER CARE

# McGovern Medical School Establishes Hematology and Medical Oncology Fellowship Program

2019 marks the first year of McGovern Medical School's Hematology and Medical Oncology Fellowship Program, built on a decade of clinical expertise and accomplishment in research. The program provides the resources fellows need to master the art and science of treating and caring for patients with blood and neoplastic disorders.

"Our goal is to train and mentor fellows to improve their clinical abilities and facilitate the development of a clinical

career or an investigative pathway for translational or clinical research," says Anneliese Gonzalez, MD, interim division director and associate professor of hematology and oncology. "The curriculum is designed to provide trainees with the analytical skills and knowledge of evidence-based medicine to care for patients with hematologic and oncologic diseases. We planned specific inpatient and outpatient clinical rotations to develop clinical excellence and encourage

academic discussion and debate."

Fellows will complete an investigative research project and career development plan. In addition to rotations at Memorial Hermann-Texas Medical Center, they will rotate to The University of Texas MD Anderson Cancer Center, the UT Physicians Gulf States Hemophilia and Thrombophilia Center-Texas Medical Center, and suburban hospitals in the Memorial

**Fellowship Program** continues on page 4

**Fellowship Program** continued from page 3

Hermann Health System. The program has been approved by the Accreditation Council for Graduate Medical Education (ACGME) for two fellows each year, for a total of six.

“We are a relatively young division and during the last decade have recruited faculty with expertise in oncology, built the clinical core of our

program, increased patient volumes and fostered important relationships with other departments – pathology, surgery and others with the expertise fellows need to finish their program as well-rounded hematologists and oncologists,” Dr. Gonzalez says.

Candidates for the fellowship program must complete three years of an internal medicine residency in an

ACGME-accredited program. Current fellows are Frances Cervoni-Curet, MD, who received her medical degree at Ponce Health Sciences University in Puerto Rico, and Wei Yang, MD, who graduated from the University of Miami Leonard M. Miller School of Medicine. Both physicians completed their residencies at McGovern Medical School.

## In Memoriam: Robert J. Amato, DO



Dr. Robert J. Amato, professor in the division of Oncology and a world leader in the treatment of genitourinary cancer, died Friday, Sept. 6, 2019. Dr. Amato was born on Nov. 19, 1956. He received his medical degree at the University of North Texas, Texas College of Osteopathic Medicine after graduating with a Bachelor of Science degree from Texas Christian University. He completed his residency program in internal medicine at the Texas College of Osteopathic Medicine Hospital System before completing fellowship training in medical oncology at The University of Texas MD Anderson Cancer Center, where he earned the top award for clinical excellence. He joined the faculty at MD Anderson Cancer Center in 1988 and in 2000, was recruited to Baylor College of Medicine as an associate professor. He joined the department of Internal Medicine, division of Oncology at McGovern

Medical School at UTHealth in September 2008 as a professor.

Early in his career, Dr. Amato’s research helped make testicular cancer a highly treatable disease. His most recent research focused on molecular-targeted therapeutics to halt the progression of metastatic kidney and prostate cancers, the further development of immunotherapies with a primary focus on vaccine and immune therapy, and determining how elements from his studies might be used in the treatment of

bladder and testicular cancer.

Dr. Amato came to UTHealth in 2008 to develop the division of Oncology. During his tenure, he recruited a mix of senior and junior faculty and oversaw much growth. He also built a robust translational and clinical research team.

“Dr. Amato singlehandedly set up the division of Oncology and jelled together the various elements to build the Memorial Hermann Cancer Center-Texas Medical Center,” says Anneliese Gonzalez, MD, interim division director and associate professor of hematology and oncology. “On the clinical side, Dr. Amato was a competent and astute clinician who was universally respected and admired. His peers valued his opinion on complex oncology cases. Patients came to see him from around the world because of his reputation, research publications and great successes in treating patients with genitourinary malignan-

cies. His dedication to his patients was matched only by their devotion to him, and he put forth tremendous energy and expertise in caring for them.”

Dr. Amato believed strongly in the value of teaching and mentorship. He shared his wide-ranging knowledge and ideas about innovations in cancer treatment with his colleagues. “He was a strong advocate and mentor for junior research faculty and took true pleasure in working with trainees and students to teach the next generation of clinician-scientists,” Dr. Gonzalez says. “He provided the environment for junior faculty to grow individually in their career paths. The impact of his work will live on in the lives of thousands of cancer patients and the future contributions of the junior faculty he mentored. He lived life to the fullest and was a true leader with a vision that we believed in. He was passionate about instilling a sense of hope, scientific curiosity and hard work in those around him. These efforts will continue to touch lives for years to come. We are grateful for the time we had with him.”

*The family of Dr. Amato would like to thank the physicians and staff at Mischer Neuroscience Institute, McGovern Medical School at UTHealth and Memorial Hermann-Texas Medical Center, who provided care for him. Contributions may be directed to the Dr. Robert Amato Memorial Fund, PO Box 1321, Houston, TX 77251-1321 or giving.uth.edu/memorial.*



As the year comes to an end, it's important to note that one of the ways we continue to enhance the cancer patient experience is through our nurse navigator

program, a service we are continuing to expand. This program is so important because it offers compassion, guidance and resources to those who trust us to care for them. Our oncology nurse navigators are a listening ear and a guiding light in a journey that can be overwhelming. This compassionate group of nurses make a difference because they are by the patient's side every step of the way during their cancer journey. You can read more about their contributions in this issue in Profiles in Caring.

We've also launched a new lay patient navigator program in part-

nership with CanCare to expand our capabilities to provide one-on-one support to cancer patients and their families. Cancare volunteers are cancer survivors and offer a unique and hopeful type of support to cancer patients.

Beyond the navigator program, Memorial Hermann has also partnered with the American Cancer Society to offer a volunteer program of survivors who can provide current patients support and resources to make their lives less stressful when undergoing treatment. You can learn more about this in the Volunteer Spotlight of this issue.

Additionally, it's a sobering fact that 1 in 8 women will be diagnosed with breast cancer in her lifetime. We must continue our efforts to ensure all women have access to breast cancer screening that could potentially save their lives. One way we accomplish this is through Project Mammogram which offers free mammograms and follow up treatment to

women who are uninsured or have high deductibles and live in zip codes served by our Memorial Hermann Northeast Hospital. Recently the 10th annual Razzle Dazzle luncheon, raised nearly \$850,000 for early detection and outreach programs at our Bobetta Lindig Breast Care Center at Memorial City.

In closing, it is through our community partnerships, fundraisers, and team of affiliated cancer physicians that we continue to improve cancer care at Memorial Hermann Health System. May you and your loved ones have the very healthiest and happiest of holidays. We look forward to serving you in 2020.

**Sandra Miller, MHSM, RN, NE-BC**  
*Vice President*  
*Memorial Hermann Oncology*  
*Service Line*



Memorial Hermann experienced a lot of wins in 2019 - from surgical and technological advances to finding new and better ways to help patients navigate their

cancer journey. We continue to strive every day to further enhance all of our programs and services and improve quality of life and survivorship for all the patients we have the pleasure of treating. In 2019, we launched our hematology and medical oncology fellowship program, which encompasses ten years of clinical expertise and research. Un-

fortunately, in September we experienced a loss of one of our own with the passing of Dr. Robert J. Amato, a well-respected oncologist and world leader in the treatment of genitourinary cancer. He was instrumental in making testicular cancer a highly treatable disease, and most recently was involved in research to stop the progression of kidney and prostate cancers. Dr. Amato's passion for teaching and mentorship will not be forgotten as our current and future residents and physicians continue his work by taking what he taught us and applying it to clinical practice. I would like to dedicate this issue of the Cancer Journal to Dr. Amato for his commitment and tireless efforts to helping patients with cancer. His contributions are a reminder of what

we must continue to strive for in order to enhance and improve the treatment and quality of life of our patients.

**Ron J. Karni, MD**  
*Chair, Oncology CPC Subcommittee*  
*Memorial Hermann Physician*  
*Network*

## Tam Huynh, MSN, RN, FNP-C, CBCN, AOCNP



Twenty years ago when Tam Huynh was certified as an RN, she applied for a job in oncology because there was an opening.

“I stayed in oncology because that’s where my heart is,” says Huynh, who is the Oncology Nurse Navigator at Memorial Hermann Cancer Center-Southeast. “A diagnosis of cancer affects our patients and everyone close to them. They have to cope with a range of emotions, lifestyle changes and financial issues. I watch them find the strength within themselves to carry on through treatment and survivorship, and I’m grateful for the opportunity to help.”

Huynh, who is bilingual in English

and Vietnamese, is an advanced oncology certified nurse practitioner, a certified breast care nurse and a family nurse practitioner. She received her MSN at Texas Woman’s University and has practiced oncology nursing for 20 years. Before joining Memorial Hermann, she served at The University of Texas MD Anderson Cancer Center, primarily in the Stem Cell and Bone Marrow Transplant Unit.

Huynh worked with urologist Kyle Keyes, MD, for six months as an Oncology Nurse Navigator at Memorial Hermann Sugar Land Hospital before transferring to Memorial Hermann Southeast in October. “Tam did a great

job of tying everything together for my patients,” Dr. Keyes says.

“She followed up the day after treatment to make sure they had all they needed. She gave them emotional support, helped with their referrals and connected them to financial support. She made sure all the boxes were checked. All my patients loved her.”

“Helping Dr. Keyes was a privilege every step of the way, and I’m happy he felt he could count on me,” she says. “Going home at the end of the day knowing I’ve helped someone is the most rewarding feeling.”

## LINAC Edge Provides Greater Radiation Precision at the Memorial Hermann Cancer Center-TMC



The Memorial Hermann Cancer Center-Texas Medical Center has acquired the new LINAC Edge® radiosurgery system, which will permit the treatment of more patients with its speed, precision and streamlined treatment planning.

“The LINAC Edge provides additional precision in terms of shaping and modulating the dose of radiation with its high-definition multileaf collimator, allowing us to pinpoint the target,” says Angel Blanco, MD, medical director of radiation oncology and Gamma Knife Centers at Memorial Hermann-Texas Medical Center and an associate professor in the Vivian L. Smith Department of Neurosurgery at McGovern Medical School at UTHealth. “This particular collimator translates to double the precision in shaping the radiation and has the capability during

stereotactic radiosurgery to treat very small targets at higher doses with high accuracy. We can deliver highly focused treatments in fewer sessions and at a faster rate, while minimizing the dose received by surrounding healthy tissues.”

During radiosurgery, the Edge tracks the patient’s tumor in real time for intracranial and extracranial treatments. With the addition of the Calypso system, purchased as an add-on, radiation oncologists can track moving targets in properly selected patients.

“The Edge monitors respiratory motion,” says Tiffany Balderas, BSRT, (R), (T), RROC, manager of radiation oncology at Memorial Hermann Memorial City Medical Center. “This enables improved targeting for selected patients with lung, liver and pancreatic tumors, which tend to move because of breathing or the shift of abdominal contents.”

# Robotic Whipple Procedure Offers Hope for Pancreatic Cancer Patients Diagnosed Early

A robust robotic pancreaticoduodenectomy program is under way at Memorial Hermann-Texas Medical Center, led by affiliated general and oncological surgeon Curtis Wray, MD, an associate professor of surgery at McGovern Medical School at UTHealth and Cancer Liaison Physician (CLP) for the Harris Health System Cancer Committee.

“When pancreatic cancer is limited to the head of the pancreas, we can offer patients a pancreaticoduodenectomy, also known as the Whipple procedure,” Dr. Wray says. “In specialized centers such as ours, outcomes for the procedure are much improved over the last 20 years.”

The Whipple procedure is a demanding operation in which the surgeon

removes the head of the pancreas, the duodenum, the gallbladder and the bile duct, followed by a complex reconstruction. In addition to pancreatic cancer, the procedure is used to treat bile duct, duodenal and periampullary cancers, pancreatic cysts and chronic pancreatitis. The robotic procedure offers surgeons the advantage of precision and gives patients the benefit of smaller incisions and a faster recovery.

“Surgery is the mainstay of curative treatment and provides a survival benefit in patients with small, localized pancreatic tumors,” Dr. Wray says. “Our goal is to remove the tumor to prevent it from spreading and prolong survival. In cases diagnosed early, there is the potential for cure of a disease

known for its poor prognosis.”

The incidence of pancreatic cancer has increased markedly over the past several decades and it now ranks as the fourth-leading cause of cancer death in the United States, according to the National Cancer Institute. Last year, the Institute estimated 55,400 new cases of pancreatic cancer in the United States, and projected 44,330 deaths.

“Ten years ago patients who were eligible for the procedure were in the hospital two to three weeks after the surgery,” Dr. Wray says. “Today most patients are discharged to home within a week following the Whipple procedure. Patients who undergo the robotic surgery are usually home within 4 to 5 days.”

## RESEARCH

### Ongoing Clinical Trials

#### LUNG CANCER

##### **ALCHEMIST A151216 - Screening Trial for A081105, E4512 and EA5142: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial**

The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, are a group of randomized clinical trials for patients with early-stage non-small cell lung cancer (NSCLC) whose tumors have been completely removed by surgery. For patients with early-stage NSCLC, there is a 50 percent chance that the cancer will come back, even after patients receive standard treatment. The ALCHEMIST trials test to see if adding targeted therapy based on patients' tumor genetics will help prevent the cancer from returning and therefore increase the number of people who may live longer. The targeted therapy would be in addition to and after the patient completes the usual standard of care treatment.

**Sponsor:** National Cancer Institute (NCI)

**ClinicalTrials.gov**

**Identifier:** NCT02194738

##### **ALCHEMIST A081105: EGFR Treatment Trial: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery**

To determine which trial is best for patients, doctors will screen them by examining a small sample of their tumor and testing it for the presence of EGFR mutations and the ALK rearrangement. Patients who have either of these alterations will then be referred to one of two treatment trials that are testing the drugs erlotinib (for EGFR mutations) or crizotinib (for the ALK rearrangement) versus observation. Patients who are negative for both EGFR and ALK alterations or are squamous-type NSCLC will be referred to the immunotherapy trial testing nivolumab. All patients screened on A151216 will be monitored for 5 years.

**Sponsor:** National Cancer Institute (NCI)

**ClinicalTrials.gov**

**Identifier:** NCT02193282

*Clinical Trials* continues on page 8

**ALCHEMIST E4512 -  
ALK Treatment Trial: Crizotinib  
in Treating Patients With Stage  
IB-IIIA Non-small Cell Lung  
Cancer That Has Been Removed  
by Surgery and ALK Fusion  
Mutations**

Mutations in EGFR are found in about 10 percent to 15 percent of non-Asian patients with NSCLC and up to 50 percent of Asian patients. Patients whose tumors test positive for an EGFR mutation will be referred to the ALCHEMIST EGFR treatment trial. In this trial, eligible patients will be randomly assigned to take the drug erlotinib or standard of care observation for up to 2 years, or until they experience unacceptable toxicity or a recurrence of their cancer. After treatment, participants' health will be monitored for up to 10 years.

**Sponsor:** National Cancer Institute (NCI)

**ClinicalTrials.gov**

**Identifier:** NCT02201992

**ALCHEMIST EA5142 -  
Immunotherapy Treatment  
Trial: Nivolumab After Surgery  
and Chemotherapy in Treating  
Patients With Stage IB-IIIA  
Non-small Cell Lung Cancer  
(ANVIL)**

Approximately 5 percent to 6 percent of people with adenocarcinoma or related types of NSCLC have the ALK genetic rearrangement. Patients whose tumors test positive for this rearrangement, known as an ALK-EML4 fusion, will be referred to the ALCHEMIST ALK treatment trial. In this trial, eligible patients will be randomly assigned to receive the drug crizotinib or standard of care observation for 2 years, or until they experience unacceptable toxicity or disease recurrence. After treatment, participants' health will be monitored for up to 10 years.

**Sponsor:** National Cancer Institute (NCI)

**ClinicalTrials.gov**

**Identifier:** NCT02595944

The ALCHEMIST immunotherapy trial was created for patients with early-stage NSCLC whose tumors do not contain the ALK or EGFR gene changes. In addition, patients with early-stage squamous-type NSCLC may also be eligible for the immunotherapy trial. Nivolumab is approved for patients with more advanced stages of NSCLC who have progressed after platinum chemotherapy. This ALCHEMIST treatment trial is testing nivolumab in patients with early-stage lung cancer. In this trial, eligible patients will be randomly assigned to receive the drug nivolumab or be observed. After treatment, participants' health will be monitored for up to 10 years.

**Lead Physician:** Syed Jafri, MD

**Contact:** Marka Lyons (Research Manager) at 713.500.6919 or marka.lyons@uth.tmc.edu.







## PROSTATE CANCER

### **TRITON2: An International, Multicenter, Open-label, Phase II Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD)**

This study is for men with metastatic, castrate-resistant prostate cancer who also have a deleterious germline or somatic BRCA1, BRCA2 or ATM mutation, whose disease has progressed despite treatment and who have not previously received a PARP inhibitor. Participants will be enrolled into 1 of 2 cohorts based on the presence or absence of measurable visceral and/or nodal disease.

Patients will receive oral rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor. The purpose of the study is to determine the benefit of PARP inhibition in metastatic, castrate-resistant prostate cancer.

**Sponsor:** Clovis Oncology

**Lead Physician:** Julie Rowe, MD

**Contact:** Marka Lyons (Research Manager) at 713.500.6919 or marka.lyons@uth.tmc.edu

**ClinicalTrials.gov**

**Identifier:** NCT02952534

### **TRITON3: An International, Randomized, Open-label, Phase III Study of the PARP Inhibitor Rucaparib vs. Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD)**

This study is for men with metastatic, castrate-resistant prostate cancer who also have a deleterious germline or somatic BRCA1, BRCA2 or ATM mutation, whose disease has progressed despite treatment and who have not previously received a PARP inhibitor. Participants will be randomly enrolled into 1 of 2 cohorts to receive either rucaparib or physician's choice of abiraterone, enzalutamide or docetaxel.

Patients will receive oral rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor. The purpose of the study is to determine the benefit of PARP inhibition in metastatic, castrate-resistant prostate cancer compared with approved standard of care.

**Sponsor:** Clovis Oncology

**Lead Physician:** Julie Rowe, MD

**Contact:** Marka Lyons (Research Manager) at 713.500.6919 or marka.lyons@uth.tmc.edu.

**Identifier:** NCT02975934

## A Handshake Between Memorial Hermann and the American Cancer Society

Twenty-year cancer survivor Jeanne Kissinger is a first-of-a-kind volunteer at Memorial Hermann through the American Cancer Society (ACS). “I volunteer for other organizations, and as a three-time cancer survivor, I wanted to share my story with other survivors and help give them the same hope of recovery I had,” says Kissinger, who has survived ovarian cancer, soft-tissue sarcoma of the leg, and melanoma. She has been an ACS volunteer at Memorial Hermann Southeast Hospital since August 2018.

Kissinger began working at Memorial Hermann Southeast after meeting with Stacie Ellis, hospital systems manager at ACS. “The American Cancer Society doesn’t normally place volunteers in hospitals, but Memorial Hermann was interested in working with us to help their oncology nurse navigators guide patients to the resources we make available,” Ellis says. “The result is an American Cancer Society-Memorial Hermann partnered volunteer program that we hope eventually to extend to all eight Memorial Hermann Cancer Centers. We started with Memorial Hermann Southeast Hospital and Memorial Hermann-Texas Medical Center and are in the process of expanding to Memorial Hermann Memorial City Medical Center.”

American Cancer Society volunteers are trained to guide cancer patients to resources that make their lives less stressful while undergoing treatment. Kissinger and other volunteers meet with inpatients and outpatients to make them aware that help is available.

“Jeanne comes in every Wednesday and is phenomenal as a volunteer,” says Coleen White, RTT (R), direc-

tor of the Memorial Hermann Cancer Center-Southeast. “She helps them with everything from making appointments to connecting them to resources ranging from help in the home and grocery shopping to transportation to their appointments. She’s an excellent listener and very empathetic because she’s been through it herself. She takes women to our wig room, shares information about resources and has been an absolute blessing. Our patients open up to her because she has the insights of a survivor. The service she provides closes the loop for us in patient care.”

the highlight of my day,” she says. “Each time I was diagnosed with cancer, I said, okay, I have cancer again, let’s get rid of it. I can’t say enough good things about the nurses in oncology. They touch my heart. I don’t know if it’s medically sound, but I believe that a huge percentage of healing comes from your attitude. Staying positive gets you through anything. I also believe that healing comes through my faith in God.”

Stacie Ellis says Kissinger has exceeded by far any expectations she has of volunteers in the Cancer Center. “Patients ask for her. She is

“I volunteer for other organizations, and as a three-time cancer survivor, I wanted to share my story with other survivors and help give them the same hope of recovery I had.”

- JEANNE KISSINGER

Kissinger sees inpatients and outpatients in the infusion suites and in radiation therapy. “I see fear on the faces of people new to treatment, especially those who are starting chemotherapy,” she says. “When I see a frightened patient, I ask them why they are afraid of recovery, because that’s what this is all about. I like visiting with them and sharing my story, hearing theirs and seeing a smile on their faces.”

Ted Yang, MD, radiation oncologist affiliated with Memorial Hermann Southeast Hospital, appreciates Kissinger’s contribution. “Jeanne has a calming presence that makes patients want to talk with her. She’s a great addition to our team here at the Cancer Center.”

Kissinger has a let’s-beat-it attitude that inspires the patients she meets. “Working with oncology patients is

a constant presence for patients and staff,” Ellis says. “She committed to four hours one day a week, but they call her in on occasions to talk with patients when she’s needed. She comes and listens. Jeanne is pretty awesome.”

Prospective volunteers must fill out an application through the Memorial Hermann Volunteer Service Program and complete a partnered American Cancer Society-Memorial Hermann interview to determine whether they are a fit for the program. They must complete HIPAA training for ACS and Memorial Hermann and go through orientation at the hospital.

For more information about the volunteer program, email [stacie.ellis@cancer.org](mailto:stacie.ellis@cancer.org)

# Memorial Hermann Rolls Out New Lay Patient Navigator Program with the Help of CanCare

CanCare is a community of survivors and caregivers who inspire cancer patients and caregivers through one-on-one support, empathy and hope. Founded in Houston in 1990, CanCare's goal is to ensure that no one faces cancer alone, a mission that aligns exactly with the philosophy of Memorial Hermann's Integrated Network Cancer Program (INCP), the only American College of Surgeons Commission on Cancer® accredited INCP in Houston and the largest in Texas. The two organizations are working together to create a lay patient navigator program at Memorial Hermann Cancer Centers that will expand the Centers' capability to provide one-on-one support to cancer patients and their families.

"We treat more cancer patients every year," says Shelita Anderson, MBA, BSN, RN, OCN, system nursing director for oncology at Memorial Hermann. "We've expanded our oncology nurse navigator program to create a better care experience for our cancer patients from screening and diagnosis through survivorship. Our lay patient navigators work with our nurse navigators and oncology social workers to enhance our ability to help patients understand what to expect during cancer care and support them through the experience."

The lay patient navigator program was launched at the Memorial Hermann Cancer Center-Texas Medical Center in September 2019, with plans for future rollouts at the hospital system's seven other Cancer Centers.

Lay patient navigators are asked to complete a free 20-hour online training course offered by the George Washington University Cancer Institute based on core competencies for oncology patient navigators. Through a series of self-paced modules, the training walks prospective volunteers through an overview of patient navigation, the basics of health care and principles of communication and professionalism. Those who complete the course

receive a certificate acknowledging their mastery of the fundamentals of navigating patients through cancer treatment.

"Our mission at CanCare is to replace fear with hope by being there for survivors, caregivers, employers and hospital and faith communities that want to provide personal and confidential support to anyone touched directly or indirectly by cancer," says Kris Kerlin, director of program services at CanCare. "We do that by facilitating one-on-one connections with a trained cancer survivor who has overcome a similar diagnosis. Our hospital volunteers also provide support in area hospitals

and infusion centers. The patient lay navigator program is a natural progression of the support we provide in hospitals."

CanCare was founded nearly 30 years ago by Anne Shaw Turnage, a colon cancer survivor, with an anonymous gift and the support of Memorial Drive Presbyterian Church in Houston. The nonprofit organization has grown into a network of 700 trained volunteers including survivors and caregivers of survivors, located in Houston, Atlanta, Colorado Springs and Charleston who provide emotional support, encouragement, hope and cancer-related resources.

## COMMUNITY OUTREACH

### Project Mammogram Provides Breast Care Services to Underserved Women in Northeast Houston

Women who are uninsured or have high deductibles, and live in zip codes served by Memorial Hermann Northeast Hospital, may qualify for free breast care services provided through Project Mammogram. A program of the Memorial Hermann Northeast Hospital Foundation, the project offers free mammograms and appropriate follow-up treatment, including ultrasound and biopsies.

"For people who would otherwise have no access to breast care, our program is a lifesaver," says Project Mammogram Coordinator Toni Schau, RN,, who will retire at the end of January 2020 after 19 years with Memorial Hermann and 11 years with the program.

Project Mammogram provides more than 600 mammograms and ultrasounds annually that typically lead to diagnosis of eight to 12 malignancies a year. It is the only program in Northeast Houston offering these services at no charge.



Toni Schau, RN

Begun in 2001 with an initial donation from the Kingwood Women's Club, which continues to support the program through donations and volunteers, Project Mammogram is also funded in part by Susan G. Komen Houston, Memorial Hermann Northeast Hospital and the Memorial Hermann Northeast Hospital Foundation's In the Pink fundraising **Project Mammogram** continues on page 12

luncheon, as well as community donations. Women who qualify receive a complete breast exam by a registered nurse. If the exam is normal, they are referred to the Memorial Hermann Breast Care Center for a screening mammogram. In the event of a suspicious finding, the staff orders a diagnostic mammogram and ultrasound.

Women with abnormal mammogram or ultrasound findings are referred to The Rose, a non-profit breast cancer organization that partners with Project Mammogram to serve insured and uninsured women in Houston and surrounding counties. If cancer is diagnosed, The Rose immediately navigates the patient to

healthcare programs that pay for services.

“In most cases, women learn that there’s nothing wrong,” Schau says. “But if you feel a lump, you want peace of mind and that’s what we provide, in addition to saving lives.”

Project Mammogram conducts educational sessions at faith-based outreach agencies in Memorial Hermann Northeast Hospital’s service area, and signs women up at the event. Qualification is based on monthly income, lack of insurance, insurance that does not cover mammograms, income too high to qualify for Medicaid, and residence within the hospital service area, which includes North Harris County, Montgomery County, Liberty County and

Dayton County.

Schau, who says her greatest accomplishment with Project Mammogram has been saving lives, plans to continue as a volunteer after she retires. “We are a program of the heart, and that’s something you don’t easily walk away from,” she says. “It’s a special program run by special people, and they are like family. Getting the word out about breast health and following through with these women is incredibly rewarding.”

Project Mammogram is located in the Memorial Hermann Cancer Center-Northeast. For more information, call 281.540.6443.

## In the Pink of Health Raises Nearly \$750,000 to Help Fight Breast and Ovarian Cancer



*Pictured is Gabby the Great Dane with Montgomery Pet Partners and her handler Dean Nistetter rounding in Administration at Memorial Hermann The Woodlands Medical Center. Gabby is decked out in her pink pearls and pink collar in recognition of National Breast Cancer Month.*

*Gabby is a cancer survivor herself, having recovered from sarcoma. The hospital’s registered therapy dogs visit patients and also make special visits to Canopy at Memorial Hermann The Woodlands.*

A crowd of more than 1,100 filled The Woodlands Waterway Marriott Hotel & Convention Center at the 19th Annual Memorial Hermann In the Pink of Health Luncheon.

Generous donors and attendees helped raise nearly \$750,000, which will be reinvested into the greater Montgomery County area to fund cutting-edge technology, programs and services for breast and ovarian cancer patients and survivors. Funds will also support Canopy, The Cancer Survivorship Center at Memorial Hermann.

“It’s inspiring to see how In the Pink of Health continues to grow since its inception nearly 20 years ago,” says Josh Urban, senior vice president and CEO of Memorial Hermann Northeast Hospital and Memorial Hermann The Woodlands Medical Center. “In the Pink of Health has raised and distributed more than \$5.5 million in our mission to reduce the incidence of breast and ovarian cancers as well as assist survivors in their journey.”

Chaired by Debra Cooper and Dee Gelsomini, the day’s festivities started with champagne and shopping. Guests

bid on exclusive Silent Auction gift packages, including Houston Texans tickets and suite passes, a golf day and spa day at the Woodlands Resort Spa, Botox® treatments, a Hawaii vacation for two and much more.

The formal luncheon and program began at noon with emcee Brady Hull welcoming guests. Christina Wells, a former Memorial Hermann nurse and America’s Got Talent semi-finalist, brought down the house with her rendition of the song “I am Changing.” At 1 p.m., keynote speaker Rick Rigsby, PhD, took the stage. An award-winning journalist, Dr. Rigsby is a *USA Today*, *Wall Street Journal* and Amazon best-seller. He lost his wife to breast cancer in 1996 and today focuses his attention on empowering people worldwide.

Sponsors of the event were Richie’s Specialty Pharmacy, Presenting Sponsor; Adcetera, Brand Patron; Makeup Junkie, Luxury Bag Pull; BMW of Houston North and BMW of The Woodlands, and Tricia and Jack Futcher, Luxury Automotive Sponsor; Mary Ann and Marty Young, Pink Diamond Sponsor; as well as Ruby Sponsors, Sapphire Sponsors,

# Memorial Hermann Celebrates 10th Anniversary of Razzle Dazzle Luncheon with Country Music Superstar Reba McEntire, Raises Record-Breaking \$850,000

A star-struck crowd of more than 650 men and women filled the ballroom of The Post Oak Hotel to celebrate the 10th anniversary of Memorial Hermann's Razzle Dazzle "Bloom" Luncheon and the inspiring sum of \$850,000 raised for early detection and outreach programs at the Bobetta C. Lindig Breast Care Center at Memorial Hermann Memorial City Medical Center. Headlining the event was three-time GRAMMY® award-winning entertainment icon, acclaimed actress and entrepreneur Reba McEntire, who participated in a live, onstage interview with KPRC-TV Channel 2 Chief Meteorologist Frank Billingsley. Chaired by well-known Houston community leaders Whitney Crane and Tony Bradfield, the event honored Bobetta Lindig for her vision in creating the center that bears her name.

"This is a disease that affects all of us and impacts families. That's why so many people at Memorial Hermann are committed and working on Razzle Dazzle," says Memorial Hermann Foundation CEO and Executive Vice President Anne E. Neeson. "The generosity of those who attended today's luncheon will allow the Memorial Hermann Bobetta Lindig Breast Care Center to continue to invest in the latest technology to create the best possible experience for patients as well as optimal outcomes. We are so grateful for our donors and community leaders."

Held at The Post Oak Hotel, the celebratory features of the milestone luncheon included the opportunity to purchase a champagne flute for \$50, entitling the purchaser to pink champagne service throughout the luncheon and a chance to win a \$10,000 Tenenbaum Jewelers gift card. Elizabeth Anthony,



Events, Macy's, Neiman Marcus, Saks Fifth Avenue, Tenenbaum Jewelers, Tootsies and Dillard's were on site selling fine jewelry, handbags, scarves, sunglasses, fragrances and holiday decor.

Medical device company Hologic was on site with a 3-D mammography unit for guests to view. Studies show that 3-D mammograms detect more invasive breast cancers compared to 2-D mammograms alone. Funds raised at Razzle Dazzle have allowed patients to access the Hologic machine at the Breast Care Center.

The Razzle Dazzle Gift Card Tree offered guests an opportunity to give \$100 in exchange for a surprise gift card worth up to \$1,500 from luxury brand designers, high-end retail establishments, popular area restaurants and sought after service providers.

KPRC news anchor Christine Noël was the perfect emcee for the glitzy luncheon. Local restaurateur and Memorial Hermann supporter Donna Vallone provided the invocation before remarks by Neeson as guests enjoyed lunch.

A moving video paid tribute to Lindig's continued support of Memorial Hermann, beginning with her husband Bill's cancer diagnosis in 1996. As a regular mammogram patient at Memo-

rial Hermann's former cancer facility, she imagined a better experience for all patients. That led to the warm robes, private dressing rooms and spa-like setting of today's center. It also gave rise to the Razzle Dazzle luncheon, which has raised more than \$3 million in its first 10 years. In addition to the Bobetta Lindig Breast Center, her family's name can also be found on the Lindig Men's Health Center and the Kate Lindig Neonatal Care Unit. "It's the greatest health system I can ever imagine being affiliated with, and I will do everything in my power to keep it that way," she says.

Stephen Lewis served as auctioneer for three live auction packages including the opportunity to throw out the first pitch at a Houston Astros game with front row Diamond Club seats, a work of art by well-known painter Ashley Longshore and a pair of Buccellati 18K white gold, yellow gold and diamond earrings.

Since its inception in 2010, Razzle Dazzle has generated more than \$3 million to support breast cancer patients and their families through the Bobetta C. Lindig Breast Care Center. Proceeds from this luncheon have provided funding for cutting-edge equipment using the latest technology. These

*Razzle Dazzle continues on page 14*

## Memorial Hermann Memorial City Holds Prostate Cancer Seminar and Breakfast

Last September, 50 people attended an informational seminar and breakfast to learn about advanced methods of screening, detection and treatment for prostate cancer. The seminar was held at the Lindig Family Cancer Resource Center at Memorial Hermann Memorial City Medical Center as part of the hospital's community outreach program.

Speakers were urologist Samit Soni, MD, who spoke on prevention, diagnosis and surgical treatment; radiation oncologist Shariq Khwaja, MD, who addressed nonsurgical and postsurgical treatment; and pelvic floor physical therapist Gail Zitterkopf, PT, DPT, CLT, who shared information about therapies for incontinence related to treatment.

"Thanks to the generosity of Houstonians Bill and Bobetta Lindig and our hospital employees, the Lindig Family Cancer Resource Center is available to provide information, emotional support and resources to help in the fight against cancer," says Alla Vargo, MBA, MHA, RDMS, ARRT(R), oncology service line director at Memorial Hermann Memorial City. "The Center includes the Lindig Resource Library, two breakout rooms for survivorship programs, a dedicated community outreach specialist and oncology nurse navigator, and a 50-seat conference center for physicians and other medical professionals, support groups and educational seminars."

According to the American Cancer Society, approximately 1 in 9 men will be diagnosed with prostate cancer during his lifetime, making it the second most common cancer in men. Today, most prostate cancers can be effectively treated and cured.

*Razzle Dazzle* continued from page 13

diagnostic tools allow detection of the tiniest tumors at their earliest stages, thus giving patients the best chance for survival.

For more information on breast cancer programs at Memorial Hermann Memorial City, visit [memorialhermann.org/breastcare](http://memorialhermann.org/breastcare) or call 713.242.3480.

### MEMORIAL HERMANN WELCOMES



**Jessica Jones, MD**, is a breast oncologist with special interest in overcoming resistance in hormone-positive breast cancer, integrating supportive care

for quality improvement, genome sequencing, pharmacogenetics and personalized medicine as it applies to breast cancer.

An assistant professor in the division of Oncology at McGovern Medical School at UTHealth, Dr. Jones received her medical degree at UT Health San Antonio Medical School. She completed a fellowship in medical oncology/hematology at the same institution, where she was awarded the Joe and Teresa Lozano Long Presidential Scholar Award in medical school, as well as the Dean's Most Promising Research Award in 2010. She was named Most Compassionate Intern and Most Compassionate Resident in 2014-15 and was awarded the prestigious McDonald Award of Excellence in Oncology in 2018 for her research in breast cancer, research mentoring and work in quality improvement. She practices at Memorial Hermann-Texas Medical Center.



**Samir Mazharuddin, MD**, joined the medical staff of Memorial Hermann Northeast Hospital after completing fellowship training in hematology and oncology at

Baylor University Medical Center in Dallas, where he also completed his residency in internal medicine. He graduated in the top quartile of his class at Texas A&M Health Science Center College of Medicine in Bryan. Dr. Mazharuddin is board certified by the American Board of Internal Medicine, and he actively participates in clinical trials. His research has been published in numerous medical journals. He is an enthusiastic long-distance runner, an avid traveler with an interest in different cultures, and is proficient in Hindi and Urdu. He is experienced with all cancers and blood disorders and is accepting patients.



**Tamara E. Saunders, MD, FACS**, an assistant professor of surgery at McGovern Medical School, maintains a surgical practice focused on breast disease. Dr. Saunders

received her medical degree at UT

*Welcome* continues on page 15

Health San Antonio Medical School and completed residency training at McGovern Medical School. Her patient care philosophy focuses on shared decision-making and integrating each breast cancer patient's unique tumor biology to develop a personalized treatment plan. She is board certified by the American Board of Surgery and is a Fellow of the American College of Surgeons. She practices at Memorial Hermann-TMC.



**Mercedes Basey-Scott, BSN, RN, PCCN, CPHON**, is an Oncology Nurse Navigator at Memorial Hermann Northeast Hospital. Basey-Scott received her BSN at Stephen F.

Austin State University in Nacogdoches in 2014, followed by an MSN and MBA in 2019 from The University of Texas at Tyler. She has worked as an oncology nurse for five years. Prior to joining Memorial Hermann, she was as a nurse at The University of Texas MD Anderson Cancer Center in a role focused on telemetry and Phase 1 clinical trials. She has also worked as a charge nurse at Texas Children's Hospital in the Bone Marrow Transplant Unit. She is certified as a Progressive Care Nurse and Pediatric Hematology and Oncology Nurse.



**Lisa Lampton, BSN, RN, OCN**, is the Oncology Nurse Navigator at Memorial Hermann Cypress and Memorial Hermann Katy Hospitals. Lampton received her Bachelor of

Science in Nursing from Texas Tech University in 2010, and has been a dedicated oncology nurse since 2012.

Before joining the Memorial Hermann Oncology Nurse Navigation team in 2019, Lampton worked as an oncology nurse case manager for UnitedHealth Group. She also has six years of experience working as a lead clinic and infusion nurse. She is certified as a chemotherapy and biotherapy provider by the Oncology Nursing Society. She helps her patients by ensuring they have the information they need during their cancer journey.



**Priscilla Rodriguez, MHS, BSN, RN**, is an Oncology Nurse Navigator for Memorial Hermann System Services. Rodriguez earned her master's degree in health admin-

istration at Texas Women's University in 2019 and her Bachelor of Science in Nursing at Prairie View A&M University in 2013. She began her nursing career at Ben Taub Hospital in Houston, and before joining Memorial Hermann, spent four years at The University of Texas MD Anderson Cancer Center working on the head, neck and breast plastic surgery oncology inpatient unit. Rodriguez is passionate about making a difference in the lives of patients as the person they can turn to while navigating their cancer journey.



**Erica Nicole Scott, BSN, RN**, is an Oncology Nurse Navigator and colorectal coordinator for Memorial Hermann Memorial City Medical Center and Memorial

Hermann The Woodlands Medical Center. She earned her bachelor's degree in nursing at The University of Texas at Arlington. She has worked as a labor and delivery nurse, OB-

GYN nurse and nurse manager. Before joining Memorial Hermann, she spent six years as a breast care nurse navigator at Emory University Hospital Breast Imaging in Atlanta, Georgia. Originally from New Orleans, Scott enjoys indulging in the culture and cuisine of Louisiana but moved back to Houston to be closer to family and friends. She says she is grateful for the opportunity to be an advocate for oncology patients and their special survivorship needs.



**Janetta Thomas, MSN, RN**, is an Oncology Nurse Navigator at Memorial Hermann Southwest Hospital. Thomas received her BSN at The University of Texas at Ar-

lington in 2012, followed by an MSN from Western Governors University in 2019. She has worked as an oncology nurse for six years. Before coming to Memorial Hermann, she worked in the Infusion Clinic at the Michael E. DeBakey VA Medical Center. She has also served as an oncology infusion nurse and as a hepatocellular carcinoma case manager at the Department of Veteran Affairs in both Austin and Temple.

#### IN PRINT

Dehghani M, Rosenblatt KP, Li L, Rakhade M, Amato RJ. Validation and Clinical Applications of a Comprehensive Next Generation Sequencing System for Molecular Characterization of Solid Cancer Tissues. *Frontiers in Molecular Biosciences*. 25 Sep 2019. doi.org/10.3389/fmolb.2019.00082.

Nonprofit Org.  
U.S. POSTAGE  
**PAID**  
Permit No. 3156  
Houston, TX

**ABOUT MEMORIAL HERMANN CANCER CENTERS**

Memorial Hermann offers the entire continuum of cancer care – education, prevention, screening, diagnosis, treatment, survivorship and rehabilitation. We do more than provide trusted medical care: we are helping patients navigate their entire cancer journey by caring for their physical, social, emotional and spiritual needs. Patients can take advantage of cancer services in their own neighborhood through our convenient network, which includes eight Cancer Centers, more than 20 breast care locations, 15 acute care hospitals and dozens of other affiliated programs.

Through partnerships and affiliations with community oncology providers, UTHealth, Mischer Neuroscience Institute at Memorial Hermann-Texas Medical Center, and TIRR Memorial Hermann, patients can be confident that oncology specialists are working together to ensure the best possible outcome for their cancer treatment. At Memorial

Hermann, we provide patients with the tools and resources needed to fight cancer close to home when home is where they want to be.


All Memorial Hermann Cancer Centers are accredited by the American College of Surgeons Commission on Cancer, and the Greater Heights Breast Cancer Center has been granted full, three-year accreditation by the National Accreditation Program for Breast Cancer.

To refer a patient or schedule an appointment, call the Memorial Hermann Cancer Center nearest you:

- Memorial City:** 866.338.1150
- Northeast:** 855.537.0016
- Greater Heights:** 855.537.0019
- Southeast:** 855.537.0017
- Texas Medical Center:** 855.537.0013
- The Woodlands:** 855.537.0015

*TIRR is a registered trademark of TIRR Foundation.*

**MEMORIAL HERMANN CANCER CENTER LOCATIONS**



- Memorial City**  
925 Gessner Rd.  
Houston, TX 77024
- Northeast**  
18960 Memorial North  
Humble, TX 77338
- Greater Heights**  
1635 North Loop West  
Houston, TX 77008
- Katy**  
23900 Katy Fwy.  
Katy, TX 77494
- Southeast**  
11920 Astoria Blvd.  
Suite 100  
Houston, TX 77089
- Southwest**  
7600 Beechnut St.  
Houston, TX 77074
- Texas Medical Center**  
6400 Fannin St., Suite 2900  
Houston, TX 77030
- The Woodlands**  
920 Medical Plaza Dr., Suite 100  
Shenandoah, TX 77380

The Memorial Hermann Cancer Journal is published three times a year by Memorial Hermann Health System. Please direct your comments or suggestions to Editor, Memorial Hermann Cancer Journal, Memorial Hermann Memorial City Tower, 929 Gessner Rd., Suite 2548, Houston, TX 77024, 713.242.4490.

To receive the Memorial Hermann Cancer Journal via email, please sign up online at [memorialhermann.org/cancerjournal](http://memorialhermann.org/cancerjournal).

**Sandra Miller, MHSM, RN, NE-BC,**  
Vice President, Memorial Hermann  
Oncology Service Line

**Ron J. Karni, MD,** Chair, Oncology CPC Subcommittee,  
Memorial Hermann Physician Network

**Heather Sessions,** Editor and Contributing Writer  
**Karen Kephart,** Writer  
**Freeman Design Associates,** Designer

Material in this publication may not be reproduced in whole or part without permission from Memorial Hermann Health System.

Winter 2019